{"id":46966,"date":"2026-03-16T13:43:32","date_gmt":"2026-03-16T11:43:32","guid":{"rendered":"https:\/\/purama.lt\/?p=46966"},"modified":"2026-04-22T14:16:19","modified_gmt":"2026-04-22T12:16:19","slug":"nmn-blakusparadibas","status":"publish","type":"post","link":"https:\/\/purama.lt\/lv\/nmn-salutinis-poveikis\/","title":{"rendered":"NMN blakuspar\u0101d\u012bbas un dro\u0161\u012bba: ko patie\u0161\u0101m liecina p\u0113t\u012bjumi ar cilv\u0113kiem?"},"content":{"rendered":"<p>Internet\u0101 par NMN ir viegli apmald\u012bties. Da\u017eviet tas tiek pasniegts gandr\u012bz k\u0101 mier\u012bgs, zin\u0101tniski pamatots ce\u013c\u0161 uz ilgm\u016b\u017e\u012bbu, citviet - k\u0101 v\u0113l viena p\u0101rv\u0113rt\u0113ta modes lieta. Kad runa ir par <strong>NMN blakuspar\u0101d\u012bbas<\/strong>, paties\u012bba \u0161eit ir maz\u0101k dramatiska, bet daudz v\u0113rt\u012bg\u0101ka: <strong>\u012bslaic\u012bgos p\u0113t\u012bjumos ar cilv\u0113kiem NMN kopum\u0101 tika labi panests.<\/strong>, ta\u010du joproj\u0101m ir p\u0101r\u0101k maz datu par ilgtermi\u0146a dro\u0161\u012bbu, lai ar rok\u0101m vicin\u0101tu un teiktu, ka \u201eviss ir skaidrs\u201c.<\/p>\n\n\n\n<p>\u0160aj\u0101 rakst\u0101 m\u0113s sniegsim vienk\u0101r\u0161u un skaidru p\u0101rskatu par to, ko m\u0113s \u0161odien zin\u0101m par <strong>NMN dro\u0161\u012bba<\/strong>, k\u0101das devas tika p\u0113t\u012btas, k\u0101das <strong>NMN blakuspar\u0101d\u012bbas<\/strong> zin\u0101tne v\u0113l neredz, un kam j\u0101saglab\u0101 piesardz\u012bba.<\/p>\n\n\n\n<p>Saturs<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"#ar-nmn-saugus\" data-type=\"internal\" data-id=\"#ar-nmn-saugus\">\u012asa atbilde: vai NMN ir dro\u0161s?<\/a><\/li>\n\n\n\n<li><a href=\"#tyrimai\" data-type=\"internal\" data-id=\"#tyrimai\">Ko liecina cilv\u0113ku p\u0113t\u012bjumi<\/a><\/li>\n\n\n\n<li><a href=\"#salutinis-poveikis\">K\u0101das NMN blakuspar\u0101d\u012bbas l\u012bdz \u0161im ir konstat\u0113tas<\/a><\/li>\n\n\n\n<li><a href=\"#ko-nezinome\">Ko m\u0113s nezin\u0101m par NMN dro\u0161\u012bbu<\/a><\/li>\n\n\n\n<li><a href=\"#kam-atsargiau\">Kam j\u0101b\u016bt uzman\u012bg\u0101kam<\/a><\/li>\n\n\n\n<li><a href=\"#praktine-isvada\">Praktisks secin\u0101jums<\/a><\/li>\n\n\n\n<li><a href=\"#duk\">BIE\u017d\u0100K UZDOTIE JAUT\u0100JUMI<\/a><\/li>\n\n\n\n<li><a href=\"#saltiniai\">Avoti:<\/a><\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ar-nmn-saugus\">Vai NMN ir dro\u0161s?<\/h2>\n\n\n\n<p><strong>Saska\u0146\u0101 ar pa\u0161reiz\u0113jiem p\u0113t\u012bjumiem ar cilv\u0113kiem NMN parasti \u012bstermi\u0146\u0101 tiek labi panests.<\/strong> P\u0113t\u012bjumos ar veseliem pieaugu\u0161ajiem un da\u017e\u0101m \u012bpa\u0161\u0101m grup\u0101m netika konstat\u0113ts konsekvents nopietna kait\u0113juma sign\u0101ls, un laboratoriskie un kl\u012bniskie r\u0101d\u012bt\u0101ji kopum\u0101 b\u016btiski nepasliktin\u0101j\u0101s.<\/p>\n\n\n\n<p>Bet \u0161eit ir svar\u012bgs \u201ebet\u201c: <strong>liel\u0101k\u0101 da\u013ca p\u0113t\u012bjumu bija nelieli un ilga ned\u0113\u013cas vai m\u0113ne\u0161us, nevis gadus.<\/strong>. T\u0101p\u0113c \u0161obr\u012bd daudz prec\u012bz\u0101k ir teikt nevis \u201eNMN ir piln\u012bgi dro\u0161s\u201c, bet gan \"NMN ir piln\u012bgi dro\u0161s\". <strong>\u201el\u012bdz \u0161im \u012bstermi\u0146a p\u0113t\u012bjumos nav konstat\u0113tas nopietnas probl\u0113mas, ta\u010du joproj\u0101m tr\u016bkst ilgtermi\u0146a dro\u0161\u012bbas datu\u201c.\u201c<\/strong>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tas \u0161\u0137iet diezgan skaidrs:<\/strong> \u012bslaic\u012bga lieto\u0161ana liel\u0101kaj\u0101 da\u013c\u0101 p\u0113t\u012bjumu tika labi panesta.<\/li>\n\n\n\n<li><strong>Kas v\u0113l nav skaidrs:<\/strong> ilgsto\u0161a lieto\u0161ana, maz\u0101k blak\u0146u un ietekme uz \u012bpa\u0161\u0101m riska grup\u0101m.<\/li>\n\n\n\n<li><strong>Kas j\u0101atceras:<\/strong> dro\u0161\u012bba un efektivit\u0101te nav viens un tas pats. Pat ja uztura bag\u0101tin\u0101t\u0101js tiek labi panests, tas nenoz\u012bm\u0113, ka t\u0101 priek\u0161roc\u012bbas jau ir pier\u0101d\u012btas visiem.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"tyrimai\">Ko liecina iedz\u012bvot\u0101ju aptaujas par NMN dro\u0161umu?<\/h2>\n\n\n\n<p>Vislab\u0101k ir s\u0101kt nevis ar rekl\u0101mas sol\u012bjumiem, bet gan ar to, kas ir re\u0101li p\u0101rbaud\u012bts uz cilv\u0113kiem. Sistem\u0101tisk\u0101 p\u0101rskat\u0101, kas public\u0113ts 2026. gad\u0101 un aptver l\u012bdz 2025. gada oktobrim public\u0113tos p\u0113t\u012bjumus ar cilv\u0113kiem un dz\u012bvniekiem, tika izdar\u012bti diezgan skarbi secin\u0101jumi: <strong>NMN cilv\u0113kiem parasti ir labi panesams ned\u0113\u013c\u0101m vai m\u0113ne\u0161iem.<\/strong>, bet kl\u012bniskie ieguvumi attiec\u012bb\u0101 uz da\u017e\u0101diem vesel\u012bbas r\u0101d\u012bt\u0101jiem ir biju\u0161i da\u017e\u0101di un bie\u017ei vien nep\u0101rliecino\u0161i.<\/p>\n\n\n\n<p>Tas kopum\u0101 atbilst iepriek\u0161 veiktajiem nejau\u0161in\u0101tiem p\u0113t\u012bjumiem. Maz\u0101kos un vid\u0113ja lieluma kl\u012bniskajos p\u0113t\u012bjumos ar veseliem pieaugu\u0161ajiem tika v\u0113rt\u0113tas da\u017e\u0101das devas, s\u0101kot no <strong>250 mg dien\u0101<\/strong> L\u012bdz <strong>1250 mg dien\u0101<\/strong>, un vien\u0101 2025. gada p\u0113t\u012bjum\u0101 slimn\u012bcas pacienti tika \u0101rst\u0113ti ar pat <strong>1000 mg divas reizes dien\u0101 14 dienas<\/strong>. \u012as\u0101k sakot, mums ir spektrs, bet tas v\u0113l nav tik pla\u0161s, lai to var\u0113tu uzskat\u012bt par piln\u012bgu st\u0101stu.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\">P\u0113t\u012bjums<\/th><th class=\"has-text-align-left\" data-align=\"left\">Iedz\u012bvot\u0101ju skaits<\/th><th class=\"has-text-align-left\" data-align=\"left\">Deva\/ilgums<\/th><th class=\"has-text-align-left\" data-align=\"left\">Kas ir pier\u0101d\u012bts attiec\u012bb\u0101 uz dro\u0161\u012bbu<\/th><\/tr><\/thead><tbody><tr><td>Gallagher et al, 2026 Sistem\u0101tisks p\u0101rskats<\/td><td>33 cilv\u0113ku intervences p\u0113t\u012bjumi<\/td><td>Da\u017e\u0101das sh\u0113mas<\/td><td>NR un NMN kopum\u0101 tika labi panesti, ta\u010du joproj\u0101m tr\u016bkst ilgtermi\u0146a dro\u0161\u012bbas un kl\u012bnisk\u0101s efektivit\u0101tes datu.<\/td><\/tr><tr><td>Pencina et al, 2025<\/td><td>Hospitaliz\u0113ti pieaugu\u0161ie ar COVID-19 un AKI<\/td><td>1000 mg 2 k.\/dien\u0101 14 dienas<\/td><td>NMN dro\u0161i paaugstin\u0101ja NAD+ l\u012bmeni; \u0161aj\u0101 \u012bsaj\u0101 p\u0113t\u012bjum\u0101 netika re\u0123istr\u0113ts neviens nopietns negat\u012bvs dro\u0161\u012bbas sign\u0101ls.<\/td><\/tr><tr><td>Yi et al, 2023<\/td><td>80 veseli pusm\u016b\u017ea pieaugu\u0161ie<\/td><td>300\/600\/900 mg, 60 dienas<\/td><td>Netika nov\u0113roti nek\u0101di nev\u0113lami blakuspar\u0101d\u012bbas, laboratorijas vai kl\u012bnisk\u0101s dro\u0161\u012bbas trauc\u0113jumi; NMN tika labi panests.<\/td><\/tr><tr><td>Okabe et al, 2022<\/td><td>30 veselas personas<\/td><td>250 mg, 12 ned\u0113\u013cas<\/td><td>Ac\u012bmredzamas blakuspar\u0101d\u012bbas vai laboratoriskas novirzes netika nov\u0113rotas.<\/td><\/tr><tr><td>Fukamizu et al, 2022<\/td><td>31 vesels pieaugu\u0161ais<\/td><td>1250 mg, 4 ned\u0113\u013cas<\/td><td>Nopietnas nev\u0113lamas blakuspar\u0101d\u012bbas netika nov\u0113rotas; prepar\u0101ts tika labi panests.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Ja visu saspie\u017eam vien\u0101 teikum\u0101, ieg\u016bstam kaut ko l\u012bdz\u012bgu: <strong>pa\u0161reiz\u0113jie dati ir vair\u0101k nomierino\u0161i nek\u0101 bied\u0113jo\u0161i, bet v\u0113l nav pietiekami, lai sl\u0113gtu durvis uz NMN ilgtermi\u0146a dro\u0161\u012bbu.<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"salutinis-poveikis\">K\u0101das blakuspar\u0101d\u012bbas l\u012bdz \u0161im ir konstat\u0113tas, lietojot NMN?<\/h2>\n\n\n\n<p>Kad cilv\u0113ki jaut\u0101 par <strong>NMN blakuspar\u0101d\u012bbas<\/strong>, vi\u0146i parasti sagaida vienu skaidru sarakstu: \u201e\u0161eit ir pieci visbie\u017e\u0101k sastopamie simptomi\u201c. Probl\u0113ma ir t\u0101, ka pa\u0161reiz\u0113jie p\u0113t\u012bjumi par cilv\u0113kiem nesniedz \u0161\u0101du skaidru un saska\u0146otu sarakstu. T\u0101 pati par sevi nav slikta zi\u0146a, bet dr\u012bz\u0101k z\u012bme, ka vismaz \u012bstermi\u0146\u0101. <strong>sp\u0113c\u012bgs, atk\u0101rtots nev\u0113lamu blakuspar\u0101d\u012bbu sign\u0101ls v\u0113l nav par\u0101d\u012bjies.<\/strong>.<\/p>\n\n\n\n<p>P\u0101rskat\u0101 par NAD+ prekursoru kl\u012bniskajiem p\u0113t\u012bjumiem 2025. gad\u0101 tika atz\u012bm\u0113ts, ka p\u0113t\u012bjumos ar cilv\u0113kiem \u0161ie savienojumi parasti bija visbie\u017e\u0101k sastopamie. <strong>dro\u0161a un labi panesama<\/strong>, un negat\u012bv\u0101s par\u0101d\u012bbas, ja t\u0101s tiek piemin\u0113tas, m\u0113dz b\u016bt vieglas. Taj\u0101 pa\u0161\u0101 laik\u0101 2025. gada sistem\u0101tiskais p\u0101rskats un metaanal\u012bze atg\u0101dina mums v\u0113l vienu svar\u012bgu aspektu: <strong>ieguvumi no m\u0101rketinga var b\u016bt liel\u0101ki nek\u0101 no kl\u012bniskajiem rezult\u0101tiem.<\/strong>. Citiem v\u0101rdiem sakot, da\u017ek\u0101rt liel\u0101kais blakusefekts ir nevis slikta d\u016b\u0161a vai galvass\u0101pes, bet gan p\u0101rm\u0113r\u012bgas cer\u012bbas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Kas l\u012bdz \u0161im ir nomierino\u0161s<\/h3>\n\n\n\n<p>\u012astermi\u0146a p\u0113t\u012bjumos <strong>nopietnas, past\u0101v\u012bgi atk\u0101rtojo\u0161\u0101s dro\u0161\u012bbas probl\u0113mas.<\/strong> nav konstat\u0113ts. Laboratoriskie, ur\u012bna un kl\u012bniskie r\u0101d\u012bt\u0101ji liel\u0101koties saglab\u0101j\u0101s fiziolo\u0123isk\u0101s robe\u017e\u0101s.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Kas joproj\u0101m nav skaidrs<\/h3>\n\n\n\n<p>Zin\u0101tne v\u0113l nevar dro\u0161i atbild\u0113t uz jaut\u0101jumu, kas notiek, ja lietojat <strong>m\u0113ne\u0161i vai gadi<\/strong>, \u012bpa\u0161i, ja personai ir blakus saslim\u0161anas vai t\u0101 lieto daudz citu uztura bag\u0101tin\u0101t\u0101ju un z\u0101\u013cu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Kas ir svar\u012bgi praks\u0113<\/h3>\n\n\n\n<p>Ja j\u016bs mekl\u0113jat atbildi uz jaut\u0101jumu \u201evai NMN ir dro\u0161s?\u201c, visgod\u012bg\u0101k\u0101 atbilde \u0161odien ir: <strong>visticam\u0101k, \u012bstermi\u0146\u0101 tas attiecas uz liel\u0101ko da\u013cu veselu pieaugu\u0161o, bet ne bez iebildumiem.<\/strong>.<\/p>\n\n\n\n<p>V\u0113l viens tre\u013c\u0161 nov\u0113rojums: <strong>\u201enav nov\u0113rotas nopietnas nev\u0113lamas blakuspar\u0101d\u012bbas\u201c nenoz\u012bm\u0113 \u201enav riska\u201c.\u201c<\/strong>. Tas noz\u012bm\u0113 tikai to, ka konkr\u0113tos p\u0113t\u012bjumos ar konkr\u0113tu dal\u012bbnieku skaitu un ierobe\u017eotu ilgumu nekas nopietns nav atkl\u0101ts. Retas, spor\u0101diskas vai ilglaic\u012bg\u0101kas blakuspar\u0101d\u012bbas \u0161\u0101dos p\u0113t\u012bjumos var nepar\u0101d\u012bties. Zin\u0101tne nav burvis, bet gan pacientu gr\u0101matvedis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ko-nezinome\">Ko m\u0113s nezin\u0101m par NMN dro\u0161\u012bbu?<\/h2>\n\n\n\n<p>\u0160eit s\u0101kas svar\u012bg\u0101k\u0101 raksta da\u013ca. Ja j\u016bs las\u012bsiet tikai rekl\u0101mas aprakstus, var izr\u0101d\u012bties, ka NMN jau ir izp\u0113t\u012bts gandr\u012bz no A l\u012bdz Z. Ta\u010du jaun\u0101kie p\u0113t\u012bjumi 2025-2026. gadam sniedz attur\u012bg\u0101ku ainu. Ir tr\u012bs galvenie tr\u016bkumi.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. Ilgtermi\u0146a pat\u0113ri\u0146\u0161<\/h3>\n\n\n\n<p>Liel\u0101k\u0101 da\u013ca no \u0161odien min\u0113tajiem p\u0113t\u012bjumiem ar cilv\u0113kiem ir veikti no <strong>14 dienas l\u012bdz 12 ned\u0113\u013cas<\/strong>. Tas ir noder\u012bgs s\u0101kums, bet nav atbilde uz jaut\u0101jumu, kas notiek, ja NMN lietojat se\u0161us m\u0113ne\u0161us, gadu vai ilg\u0101k. 2025 m. Nature Reviews Endocrinology p\u0101rskat\u0101 skaidri uzsv\u0113rts, ka joproj\u0101m ir nepiecie\u0161ami pla\u0161\u0101ki p\u0113t\u012bjumi, lai pal\u012bdz\u0113tu noteikt <strong>optim\u0101lo devu, lieto\u0161anas bie\u017eumu un ilgtermi\u0146a dro\u0161\u012bbu.<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Ne visas cilv\u0113ku grupas ir p\u0101rbaud\u012btas norm\u0101li<\/h3>\n\n\n\n<p>Ir veikti daudzi p\u0113t\u012bjumi par <strong>veseli pieaugu\u0161ie pusm\u016b\u017ea vai vec\u0101ka gadag\u0101juma cilv\u0113ki.<\/strong>. Tas noz\u012bm\u0113, ka gr\u016btniec\u0113m un sieviet\u0113m, kas baro b\u0113rnu ar kr\u016bti, b\u0113rniem, cilv\u0113kiem ar sare\u017e\u0123\u012bt\u0101m aknu, nieru vai onkolo\u0123isk\u0101m slim\u012bb\u0101m, k\u0101 ar\u012b cilv\u0113kiem, kas lieto daudz medikamentu, ir maz\u0101k skaidr\u012bbas. Tas nenoz\u012bm\u0113, ka NMN vi\u0146iem noteikti ir kait\u012bgs; tas noz\u012bm\u0113, ka <strong>mums vienk\u0101r\u0161i nav pietiekami daudz tie\u0161u datu<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3. Dro\u0161\u012bba nav vien\u0101da ar pier\u0101d\u012btiem ieguvumiem<\/h3>\n\n\n\n<p>Metaanal\u012bzes par 2024-2025. gada periodu konsekventi liecina par vienu lietu: <strong>NMN paaugstina NAD+ l\u012bmeni asin\u012bs<\/strong>. Tom\u0113r attiec\u012bb\u0101 uz daudziem praktiski svar\u012bgiem rezult\u0101tiem - glik\u0113miju, lip\u012bdiem vai fiziskaj\u0101m funkcij\u0101m - ietekme bija neviendab\u012bga, un da\u017e\u0101s anal\u012bz\u0113s b\u016btisks ieguvums netika konstat\u0113ts. Tas ir svar\u012bgi, jo dro\u0161\u012bbas jaut\u0101jums bie\u017ei vien tiek p\u0101rdots, solot lielu efektu. Zin\u0101tniskie dati l\u012bdz \u0161im liecina: bio\u0137\u012bmiskais efekts ir, bet kl\u012bniskais st\u0101sts v\u0113l nav uzrakst\u012bts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"kam-atsargiau\">Kam vajadz\u0113tu b\u016bt uzman\u012bg\u0101kam ar NMN?<\/h2>\n\n\n\n<p>Pat ja pa\u0161reiz\u0113jie dati par <strong>NMN dro\u0161\u012bba<\/strong> izskat\u0101s labi, ir cilv\u0113ku grupas, kur\u0101m ir lo\u0123iski piem\u0113rot augst\u0101kus apr\u016bpes standartus. Ne t\u0101p\u0113c, ka mums oblig\u0101ti ir slikti dati, bet t\u0101p\u0113c, ka <strong>vienk\u0101r\u0161i nav pietiekami daudz labu datu.<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Liel\u0101kas piesardz\u012bbas grupas<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gr\u016btniec\u012bba un baro\u0161ana ar kr\u016bti<\/strong> - praktiski nav datu par cilv\u0113kiem.<\/li>\n\n\n\n<li><strong>B\u0113rni un pusaud\u017ei<\/strong> - Pa\u0161reiz\u0113jos p\u0113t\u012bjumos galven\u0101 uzman\u012bba piev\u0113rsta pieaugu\u0161ajiem.<\/li>\n\n\n\n<li><strong>Cilv\u0113ki ar sare\u017e\u0123\u012btiem aknu vai nieru darb\u012bbas trauc\u0113jumiem<\/strong> - Kl\u012bniskie dati ir nepietiekami, un individu\u0101lie riski var at\u0161\u0137irties.<\/li>\n\n\n\n<li><strong>Cilv\u0113ki, kuri lieto daudz medikamentu<\/strong> - Joproj\u0101m tr\u016bkst kvalitat\u012bvu datu par iesp\u0113jamo mijiedarb\u012bbu re\u0101laj\u0101 dz\u012bv\u0113.<\/li>\n\n\n\n<li><strong>Cilv\u0113ki, kas sa\u0146em \u0101rst\u0113\u0161anu akt\u012bvu smagu slim\u012bbu d\u0113\u013c<\/strong> - jo \u012bpa\u0161i, ja \u0101rst\u0113\u0161ana ir sare\u017e\u0123\u012bta, pa\u0161\u0101rst\u0113\u0161an\u0101s ar uztura bag\u0101tin\u0101t\u0101jiem nav gudr\u0101kais pl\u0101ns.<\/li>\n<\/ul>\n\n\n\n<p>Praks\u0113 tas noz\u012bm\u0113 vienu vienk\u0101r\u0161u lietu: ja esat vesels pieaugu\u0161ais un nov\u0113rt\u0113jat. <strong>NMN blakuspar\u0101d\u012bbas<\/strong> skatoties caur pa\u0161reiz\u0113jo p\u0113t\u012bjumu prizmu, aina ir diezgan mier\u012bga. Ja piederat pie iepriek\u0161 min\u0113taj\u0101m grup\u0101m, ir v\u0113rts risin\u0101t \u0161o jaut\u0101jumu individu\u0101li, nevis pa\u013cauties tikai uz soci\u0101lo t\u012bklu entuziasmu.<\/p>\n\n\n\n<p>\u0160eit ir v\u0113rts atcer\u0113ties ar\u012b regulat\u012bvo kontekstu. ASV FDA skaidri atg\u0101dina, ka <strong>uztura bag\u0101tin\u0101t\u0101ju nekait\u012bgums un efektivit\u0101te netiek \u201eapstiprin\u0101ta\u201c t\u0101pat k\u0101 z\u0101\u013cu.<\/strong>. Ar\u012b Eiropas Komisijas publiskaj\u0101 \u201ejauno p\u0101rtikas produktu\u201c re\u0123istr\u0101 NMN ir iek\u013cauts k\u0101 jauns p\u0101rtikas produkts, kas noz\u012bm\u0113, ka regulat\u012bvais konteksts nav vienk\u0101r\u0161s vai vienots visos tirgos. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"praktine-isvada\">Praktisks secin\u0101jums: ko no t\u0101 visa secin\u0101t?<\/h2>\n\n\n\n<p>Ja \u0161o pantu sa\u012bsin\u0101tu l\u012bdz vienai rindkopai, tas b\u016btu \u0161\u0101ds: <strong>pa\u0161reiz\u0113jie p\u0113t\u012bjumi ar cilv\u0113kiem neliecina par izteikt\u0101m vai atk\u0101rtot\u0101m NMN blakuspar\u0101d\u012bb\u0101m \u012bstermi\u0146\u0101.<\/strong>, jo \u012bpa\u0161i veseliem pieaugu\u0161ajiem, bet <strong>jaut\u0101jumi par ilgtermi\u0146a dro\u0161\u012bbu, \u012bpa\u0161\u0101m riska grup\u0101m un re\u0101lo kl\u012bnisko ietekmi v\u0113l nav piln\u012bb\u0101 atbild\u0113ti.<\/strong>.<\/p>\n\n\n\n<p>T\u0101p\u0113c vislab\u0101k\u0101 poz\u012bcija \u0161odien ir nevis fan\u0101tisks \u201et\u0101 ir revol\u016bcija\u201c un panisks \u201etas ir patie\u0161\u0101m b\u012bstami\u201c, bet gan m\u0113rens v\u0113rt\u0113jums:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>J\u0101, NMN dro\u0161ums \u012bstermi\u0146a p\u0113t\u012bjumos \u0161\u0137iet labs;<\/strong><\/li>\n\n\n\n<li><strong>N\u0113, tas nenoz\u012bm\u0113, ka ilgtermi\u0146a riski ir gal\u012bgi noskaidroti;<\/strong><\/li>\n\n\n\n<li><strong>Un n\u0113, tikai NAD+ palielin\u0101\u0161an\u0101s asin\u012bs nav tas pats, kas garant\u0113ts ieguvums vesel\u012bbai.<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Kur las\u012bt vair\u0101k?<\/h3>\n\n\n\n<p>Ja v\u0113laties vair\u0101k inform\u0101cijas par pa\u0161u savienojumu, s\u0101ciet ar \u0161\u0101du inform\u0101ciju <a href=\"https:\/\/purama.lt\/lv\/nmn-celvedis\/\">NMN ce\u013cvedis<\/a>.<\/p>\n\n\n\n<p>Ja v\u0113laties uzzin\u0101t, k\u0101 at\u0161\u0137iras divi visbie\u017e\u0101k sal\u012bdzin\u0101mie NAD+ prekursori, lasiet \u0161o noda\u013cu. <a href=\"https:\/\/purama.lt\/lv\/nmn-vs-nr\/\">NMN pret NR<\/a>.<\/p>\n\n\n\n<p>Ja v\u0113laties uzzin\u0101t, ko p\u0113t\u012bjumi patie\u0161\u0101m r\u0101da, ieskatieties. <a href=\"https:\/\/purama.lt\/lv\/nmn-miti\/\">NMN m\u012bti<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"duk\">Bie\u017ei uzdotie jaut\u0101jumi par NMN blakuspar\u0101d\u012bb\u0101m<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Vai NMN ir blakuspar\u0101d\u012bbas?<\/h3>\n\n\n\n<p>\u012astermi\u0146a p\u0113t\u012bjumos ar cilv\u0113kiem <strong>skaidru un konsekventu NMN blakuspar\u0101d\u012bbu sarakstu.<\/strong> nav nov\u0113rots. Daudzos p\u0113t\u012bjumos tas ir labi panesams, bet datu par ilgtermi\u0146a lieto\u0161anu v\u0113l tr\u016bkst.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Vai NMN ir dro\u0161s ikdienas lieto\u0161anai?<\/h3>\n\n\n\n<p>Pieejamie p\u0113t\u012bjumi liecina, ka <strong>ikdienas lieto\u0161ana ned\u0113\u013c\u0101m vai m\u0113ne\u0161iem<\/strong> vairums p\u0113t\u012bto pieaugu\u0161o labi panesa. Tom\u0113r jaut\u0101jums par ilgtermi\u0146a lieto\u0161anu, piem\u0113ram, gadu vai ilg\u0101k, paliek atkl\u0101ts.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">K\u0101das NMN devas ir p\u0113t\u012btas cilv\u0113kiem?<\/h3>\n\n\n\n<p>Public\u0113tajos p\u0113t\u012bjumos ar cilv\u0113kiem ir nov\u0113rt\u0113tas sh\u0113mas, s\u0101kot no <strong>250 mg dien\u0101<\/strong> L\u012bdz <strong>1250 mg dien\u0101<\/strong> \u012bs\u0101ku laiku, un vien\u0101 2025. gad\u0101 veiktaj\u0101 p\u0113t\u012bjum\u0101 tika izmantoti stacion\u0101rie pacienti. <strong>1000 mg divas reizes dien\u0101<\/strong> 14 dienas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Vai ir pier\u0101d\u012btas NMN priek\u0161roc\u012bbas un t\u0101 dro\u0161\u012bba?<\/h3>\n\n\n\n<p>N\u0113. Pa\u0161reiz\u0113jie pier\u0101d\u012bjumi liecina, ka NMN palielina NAD+ l\u012bmeni, bet <strong>kl\u012bniskais ieguvums attiec\u012bb\u0101 uz daudziem vesel\u012bbas r\u0101d\u012bt\u0101jiem joproj\u0101m ir nevienm\u0113r\u012bgs.<\/strong>. Zin\u0101tne \u0161eit ir daudz piesardz\u012bg\u0101ka nek\u0101 rekl\u0101mas kopija.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">K\u0101p\u0113c mums vajadz\u0113tu b\u016bt piesardz\u012bg\u0101kiem attiec\u012bb\u0101 uz NMN?<\/h3>\n\n\n\n<p>Liel\u0101ka piesardz\u012bba nepiecie\u0161ama gr\u016btniec\u012bbas un z\u012bd\u012b\u0161anas period\u0101, b\u0113rniem, cilv\u0113kiem ar sare\u017e\u0123\u012bt\u0101m hronisk\u0101m slim\u012bb\u0101m vai cilv\u0113kiem, kuri lieto vair\u0101kus medikamentus, jo \u0161\u0101das grupas. <strong>ir p\u0101r\u0101k maz kvalitat\u012bvu tie\u0161o datu<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"saltiniai\">Avoti:<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41655607\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gallagher C, Emmanuel OO. NAD\u207a papildin\u0101\u0161ana pret noveco\u0161anu un labsaj\u016btai: PRISMA vad\u012bts pirmskl\u012bnisko un kl\u012bnisko pier\u0101d\u012bjumu sistem\u0101tisks p\u0101rskats. Ageing Research Reviews. 2026.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40746868\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pencina KM et al. MIB-626 (\u03b2 nikot\u012bnam\u012bda mononukleot\u012bds) dro\u0161i paaugstina NAD l\u012bmeni asin\u012bs hospitaliz\u0113tiem pacientiem ar COVID-19 un ak\u016btu nieru traumu. FASEB BioAdvances. 2025.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926126\/\" target=\"_blank\" rel=\"noreferrer noopener\">Fang EF et al. Jaunas strat\u0113\u0123ijas, pielietojumi un izaicin\u0101jumi, kas saist\u012bti ar NAD+ m\u0113r\u0137tiec\u012bgu izmanto\u0161anu kl\u012bnik\u0101. Nature Reviews Endocrinology. 2025.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39116016\/\" target=\"_blank\" rel=\"noreferrer noopener\">Zhang J, Poon ETC, Wong SHS. Peror\u0101las nikot\u012bnam\u012bda mononukleot\u012bda piedevas efektivit\u0101te glikozes un lip\u012bdu metabolism\u0101 pieaugu\u0161ajiem: sistem\u0101tisks p\u0101rskats ar nejau\u0161in\u0101ti kontrol\u0113tu p\u0113t\u012bjumu metaanal\u012bzi. Critical Reviews in Food Science and Nutrition. 2025.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36482258\/\" target=\"_blank\" rel=\"noreferrer noopener\">Yi L et al. The efficacy and safety of \u03b2-nicotinamide mononucleotide supplementation in healthy middle-aged adults. 2023.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35479740\/\" target=\"_blank\" rel=\"noreferrer noopener\">Okabe K et al. Nikot\u012bnam\u012bda mononukleot\u012bda peror\u0101la lieto\u0161ana ir dro\u0161a un efekt\u012bvi paaugstina NAD l\u012bmeni veseliem cilv\u0113kiem. Frontiers in Nutrition. 2022.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36002548\/\" target=\"_blank\" rel=\"noreferrer noopener\">Fukamizu Y et al. \u03b2-nikot\u012bnam\u012bda mononukleot\u012bda peror\u0101las lieto\u0161anas dro\u0161\u012bbas nov\u0113rt\u0113jums veseliem pieaugu\u0161iem v\u012brie\u0161iem un sieviet\u0113m. Scientific Reports. 2022.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\/food\/dietary-supplements\/information-select-dietary-supplement-ingredients-and-other-substances\" target=\"_blank\" rel=\"noreferrer noopener\">FDA. Inform\u0101cija par atsevi\u0161\u0137\u0101m uztura bag\u0101tin\u0101t\u0101ju sast\u0101vda\u013c\u0101m un cit\u0101m viel\u0101m. Atjaunin\u0101ts 2025.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/food.ec.europa.eu\/food-safety\/novel-food\/consultation-process-novel-food-status_en\" target=\"_blank\" rel=\"noreferrer noopener\">Eiropas Komisija. Apsprie\u0161an\u0101s process par jaunu p\u0101rtikas produktu statusu - nikot\u012bnam\u012bda mononukleot\u012bds. P\u0101rskat\u012bts 2026. gad\u0101.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/food.ec.europa.eu\/food-safety\/novel-food\/authorisations\/summary-applications-and-notifications_en\" target=\"_blank\" rel=\"noreferrer noopener\">Eiropas Komisija. Pieteikumu un pazi\u0146ojumu kopsavilkums - Pieteikumi par jauniem p\u0101rtikas produktiem, tostarp NMN. P\u0101rskat\u012bts 2026. gad\u0101.<\/a><\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"<p>Internete apie NMN lengva pasiklysti. Vienur jis pateikiamas beveik kaip ramus, moksli\u0161kas kelias \u012f ilgaam\u017ei\u0161kum\u0105, kitur \u2013 kaip dar viena pervertinta mada. Kai kalba pasisuka apie NMN \u0161alutin\u012f poveik\u012f, tiesa \u010dia ma\u017eiau dramati\u0161ka, bet daug vertingesn\u0117: trumpalaikiuose \u017emoni\u0173 tyrimuose NMN da\u017eniausiai buvo gerai toleruojamas, ta\u010diau ilgalaikio saugumo duomen\u0173 vis dar per ma\u017eai, kad b\u016bt\u0173 galima [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":46967,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[310],"tags":[],"class_list":["post-46966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ilgaamziskumo-gidas"],"acf":[],"_links":{"self":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts\/46966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/comments?post=46966"}],"version-history":[{"count":0,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts\/46966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/media\/46967"}],"wp:attachment":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/media?parent=46966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/categories?post=46966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/tags?post=46966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}